Ligocyte Pharmaceuticals, Inc.
|Ligocyte Pharmaceuticals, Inc. Patent applications|
|Patent application number||Title||Published|
|20130028933||METHODS FOR STABILIZING INFLUENZA ANTIGEN ENVELOPED VIRUS-BASED VIRUS-LIKE PARTICLE SOLUTIONS - Methods of stabilizing solutions with enveloped vims-based virus-like particles containing an influenza antigen and such stabilized solutions are described.||01-31-2013|
|20120093855||RSV F VLPs AND METHODS OF MANUFACTURE AND USE THEREOF - The present invention relates to the field of isolation of enveloped virus-based virus-like particles (VLPs) free of infectious agents. In preferred examples, the field includes methods of inactivation of infectious agents that do not adversely affect the immunogenicity of the enveloped virus-based VLPs. In certain embodiments, the enveloped virus-based VLPs are produced in insect cell based expression systems.||04-19-2012|
|20110195113||VIRUS-LIKE PARTICLES COMPRISING COMPOSITE CAPSID AMINO ACID SEQUENCES FOR ENHANCED CROSS REACTIVITY - The present invention provides polypeptides having a composite amino acid sequence derived from a consensus sequence representing the capsid proteins of two or more circulating strains of a non-enveloped virus. In particular, the invention provides virus-like particles comprising at least one composite polypeptide. Such virus-like particles have antigenic epitopes of two or more circulating strains of a non-enveloped virus and produce an increase in antisera cross-reactivity to one or more circulating strains of the non-enveloped virus. Methods of making composite virus-like particles and vaccine formulations comprising composite virus-like particles are also disclosed.||08-11-2011|
|20100266636||METHOD OF CONFERRING A PROTECTIVE IMMUNE RESPONSE TO NOROVIRUS - The present invention relates to vaccine compositions comprising||10-21-2010|
|20100074915||CHIMERIC INFLUENZA VIRUS-LIKE PARTICLES - Chimeric Influenza virus-like particles including gag polypeptides are described. Virus-like particles are generated with a gag polypeptide, a neuraminidase polypeptide and optionally a hemagglutinin polypeptide. Preferred methods of generation include expression in insect cells.||03-25-2010|
|20100047266||CHIMERIC VIRUS-LIKE PARTICLES - Chimeric virus-like particles including gag polypeptides are described. Virus-like particles are generated with a gag polypeptide and lipid raft-associated polypeptide linked to an antigen that is not naturally associated with a lipid raft. Preferred methods of generation include expression in insect cells.||02-25-2010|
Patent applications by Ligocyte Pharmaceuticals, Inc.